Modulation of Muscle Protein Synthesis With Diet and Exercise in Old Aged Women

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

48 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-01-31

Study Completion Date

2018-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study will measure differences in how muscle responds to both exercise and protein supplements in healthy women aged 60-69. We are studying two different protein supplements- a standard Whey Protein and a Leucine enriched supplement. Each patient would receive either one of these.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessing the Impact of a Leucine Enriched Whey Protein vs Isonitrogenous Whey on Muscle Protein Synthetic Responses in the Rested and Acute Post Exercise States in Older Adults

NCT06971822

Healthy Male Volunteers Over 65

RECRUITING NA

Leucine Supplementation Strategies to Enhance Muscle Anabolic Responses in Older Age

NCT06567665

Muscle Protein Synthesis

RECRUITING NA

Nutrition Ameliorates the Muscle Loss of Pre-sarcopenia in Elderly

NCT07309120

Low Muscle Mass Low Muscle Strength Low Physical Function

COMPLETED NA

Effect of an EAA/Whey Composition on Protein Metabolism

NCT03502941

Sarcopenia

COMPLETED NA

Amino Acid Bioavailability in Healthy Elderly After Intake of an Oral Nutritional Supplement

NCT02013466

Sarcopenia

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

One of the factors that plays an important role in the loss of functional performance and, as such, the capacity to maintain a healthy, active lifestyle is the progressive loss of skeletal muscle mass with ageing (i.e., sarcopenia). Indeed, sarcopenia is a more robust predictor of functional status and mortality in the elderly than chronological age or indeed, any other co-morbidity. Sarcopenia is an incipient process whereby lean muscle mass contributing up to \~50% of total body weight in young adults declines to \~25% when reaching the age of 75-80 y. Adequate nutritional intake, and in particular dietary protein, is important for offsetting age-related declines in muscle mass. The aim of this project is to seek the most effective nutrition with which to counteract sarcopenia, specifically in women.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy post-menopausal females aged 60-70

Exclusion Criteria

* • Obvious muscle wasting.

* A body mass index (BMI) \< 18 or \> 40 kg•m2.
* Active cardiovascular disease: uncontrolled high blood pressure, angina, heart failure (class III/IV), abnormal heart rhythm, right to left cardiac shunt or recent cardiac event.
* Taking statin-based medication above 60mg•day-1.
* Individuals taking beta-adrenergic blocking agents or Non-steroidal anti-inflammatory agents (NSAIDS)
* Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial).
* Respiratory disease including pulmonary hypertension, chronic obstructive pulmonary disease (COPD), asthma or a forced expiratory volume (FEV1) less than 1.5 litres.
* Metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, types 1 or 2 diabetes.
* Active inflammatory bowel disease, renal disease, or malignancy.
* Recent steroid treatment (within 6 months), or hormone replacement therapy.
* Clotting dysfunction e.g. Deep vein thrombosis, pulmonary embolus, warfarin therapy and/ or haemophilia.
* Musculoskeletal or neurological disorders.
* Any leg amputated
* Family history of early (\<55y) death from cardiovascular disease.
* Known sensitivity to SONOVUE (US contrast).

Minimum Eligible Age

60 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes